期刊文献+

NOD2/CARD15 gene mutations in North Algerian patients with inflammatory bowel disease 被引量:3

NOD2/CARD15 gene mutations in North Algerian patients with inflammatory bowel disease
下载PDF
导出
摘要 AIM: To analyse allelic frequency of NOD2 gene variantsand to assess their correlation with inflammatory bowel disease(IBD) in Algeria.METHODS: We studied 132 unrelated patients diagnosed with IBD, 86 with Crohn's disease(CD) and 46 with ulcerative colitis(UC). Data was prospectively collected between January 2011 and December 2013. The demographic and clinical characteristics were recorded for all the patients. A group of 114 healthy unrelated individuals were selected as controls. All groups studied originated from different regions of North Algeria and confirmed the Algerian origin of their parents and grandparents. Informed and written consent was obtained from each of the participants. All individuals were genotyped for the three CDassociated NOD2 variants(p.Arg702 Trp, p.Gly908 Arg and p.Leu1007 fsins C mutations) using the polymerase chain reaction-restriction fragment length polymorphism method. Allele and genotype frequencies in patients and control subjects were compared by χ2 test and Fisher's exact test where appropriate. Odds ratios(OR) and 95% confidence intervals(95%CI) were also estimated. Association analyses were performed to study the influence of these variants on IBD and on clinical phenotypes.RESULTS: The p.Arg702 Trp mutation showed the highest frequency in CD patients(8%) compared to UC patients(2%)(P = 0.09, OR = 3.67, 95%CI: 0.48-4.87) and controls(5%)(P = 0.4, OR = 1.47, 95%CI: 0.65-3.31). In CD patients allelic frequencies of p.Gly908 Arg and p.Leu1007 fsins C variants compared to HC were 3% vs 2%(P = 0.5, OR = 1.67, 95%CI: 0.44-6.34); 2% vs 1%(P = 0.4 OR = 2.69 95%CI: 0.48-14.87 respectively). In UC patients, allelic frequencies of p.Gly908 Arg and p.Leu1007 fsins C variants compared to HC were 1% vs 2%(P = 1, OR = 1.62, 95%CI: 0.17-4.74) and 2% vs 1%(P = 0.32, OR = 0.39, 95%CI: 0.05-2.87). The total frequency of the mutated NOD2 chromosomes was higher in CD(13%), than in HC(8%) and UC(5%). In addition, NOD2 variants were linked to a particular clinical sub-phenotype in CD in this Algerian cohort. As expected, the three NOD2 variants showed a significant association with CD but did not reach statistical significance, despite the fact that the allele frequency of NOD2 variants was in the range found in most of the European populations. This might be due to the non-exposure of the NOD2 carriers to environmental factors, required for the expression of the disease.CONCLUSION: Further analyses are necessary to study genetic and environmental factors in IBD in the Algerian population, using larger patient groups. AIM: To analyse allelic frequency of NOD2 gene variantsand to assess their correlation with inflammatory bowel disease(IBD) in Algeria.METHODS: We studied 132 unrelated patients diagnosed with IBD, 86 with Crohn's disease(CD) and 46 with ulcerative colitis(UC). Data was prospectively collected between January 2011 and December 2013. The demographic and clinical characteristics were recorded for all the patients. A group of 114 healthy unrelated individuals were selected as controls. All groups studied originated from different regions of North Algeria and confirmed the Algerian origin of their parents and grandparents. Informed and written consent was obtained from each of the participants. All individuals were genotyped for the three CDassociated NOD2 variants(p.Arg702 Trp, p.Gly908 Arg and p.Leu1007 fsins C mutations) using the polymerase chain reaction-restriction fragment length polymorphism method. Allele and genotype frequencies in patients and control subjects were compared by χ2 test and Fisher's exact test where appropriate. Odds ratios(OR) and 95% confidence intervals(95%CI) were also estimated. Association analyses were performed to study the influence of these variants on IBD and on clinical phenotypes.RESULTS: The p.Arg702 Trp mutation showed the highest frequency in CD patients(8%) compared to UC patients(2%)(P = 0.09, OR = 3.67, 95%CI: 0.48-4.87) and controls(5%)(P = 0.4, OR = 1.47, 95%CI: 0.65-3.31). In CD patients allelic frequencies of p.Gly908 Arg and p.Leu1007 fsins C variants compared to HC were 3% vs 2%(P = 0.5, OR = 1.67, 95%CI: 0.44-6.34); 2% vs 1%(P = 0.4 OR = 2.69 95%CI: 0.48-14.87 respectively). In UC patients, allelic frequencies of p.Gly908 Arg and p.Leu1007 fsins C variants compared to HC were 1% vs 2%(P = 1, OR = 1.62, 95%CI: 0.17-4.74) and 2% vs 1%(P = 0.32, OR = 0.39, 95%CI: 0.05-2.87). The total frequency of the mutated NOD2 chromosomes was higher in CD(13%), than in HC(8%) and UC(5%). In addition, NOD2 variants were linked to a particular clinical sub-phenotype in CD in this Algerian cohort. As expected, the three NOD2 variants showed a significant association with CD but did not reach statistical significance, despite the fact that the allele frequency of NOD2 variants was in the range found in most of the European populations. This might be due to the non-exposure of the NOD2 carriers to environmental factors, required for the expression of the disease.CONCLUSION: Further analyses are necessary to study genetic and environmental factors in IBD in the Algerian population, using larger patient groups.
出处 《World Journal of Gastroenterology》 SCIE CAS 2015年第25期7786-7794,共9页 世界胃肠病学杂志(英文版)
基金 Supported by the Agence Thématique de la Recherche Scientifique en Santé,(ATRSS,ex ANDRS)(PNR N°37-ANDRS-2011)
关键词 Algeria Crohn's DISEASE ULCERATIVE colitis Inflammatory BOWEL DISEASE NOD2 mutations polymerasechain reaction-restriction fragment length polymorphismmethod Algeria Crohn's disease Ulcerative colitis Inflammatory bowel disease NOD2 mutations Polymerase chain reaction-restriction fragment length polymorphism method
  • 相关文献

参考文献36

  • 1Hugot JP, Laurent-Puig P, Gower-Rousseau C, Olson JM, LeeJC, Beaugerie L, Naom I, Dupas JL, Van Gossum A, Orholm M,Bonaiti-Pellie C, Weissenbach J, Mathew CG, Lennard-Jones JE,Cortot A, Colombel JF, Thomas G. Mapping of a susceptibilitylocus for Crohn disease on chromosome 16. Nature 1996; 379:821-823 [PMID: 8587604 DOI: 10.1038/379821a0].
  • 2Brant SR, Fu Y, Fields CT, Baltazar R, Ravenhill G, Pickles MR,Rohal PM, Mann J, Kirschner BS, Jabs EW, Bayless TM, HanauerSB, Cho JH. American families with Crohn disease have strongevidence for linkage to chromosome 16 but not chromosome 12.Gastroenterology 1998; 115: 1056-1061 [PMID: 9797357 DOI:10.1016/S0016-5085(98)70073-3].
  • 3Annese V, Latiano A, Bovio P, Forabosco P, Piepoli A, LombardiG, Andreoli A, Astegiano M, Gionchetti P, Riegler G, SturnioloGC, Clementi M, Rappaport E, Fortina P, Devoto M, Gasparini P,Andriulli A. Genetic analysis in Italian families with inflammatorybowel disease supports linkage to the IBD1 locus-a GISC study.Eur J Hum Genet 1999; 7: 567-573 [PMID: 10439963 DOI:10.1038/sj.ejhg.5200328].
  • 4Sabbah A, Chang TH, Harnack R, Frohlich V, Tominaga K,Dube PH, Xiang Y, Bose S. Activation of innate immune antiviralresponses by Nod2. Nat Immunol 2009; 10: 1073-1080 [PMID:19701189 DOI: 10.1038/ni.1782].
  • 5Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, CrespoJ, Fukase K, Inamura S, Kusumoto S, Hashimoto M, Foster SJ,Moran AP, Fernandez-Luna JL, Nuz G. Host recognition ofbacterial muramyl dipeptide mediated through NOD2. Implicationsfor Crohn disease. J Biol Chem 2003; 278: 5509-5512 [PMID:12514169 DOI: 10.1074/jbc.C200673200].
  • 6Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, NunezG. Nod2, a Nod1/Apaf-1 family member that is restricted tomonocytes and activates NF-kappaB. J Biol Chem 2001; 276:4812-4818 [PMID: 11087742 DOI: 10.1074/jbc.M008072200].
  • 7Gutierrez O, Pipaon C, Inohara N, Fontalba A, Ogura Y,Prosper F, Nunez G, Fernandez-Luna JL. Induction of Nod2 inmyelomonocytic and intestinal epithelial cells via nuclear factorkappaB activation. J Biol Chem 2002; 277: 41701-41705 [PMID:12194982 DOI: 10.1074/jbc.M206473200].
  • 8Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, Hner R, Chamaillard M, Zouali H, Thomas G, Hugot JP.CARD15 mutations in Blau syndrome. Nat Genet 2001; 29: 19-20[PMID: 11528384 DOI: 10.1038/ng720].
  • 9Okafuji I, Nishikomori R, Kanazawa N, Kambe N, Fujisawa A,Yamazaki S, Saito M, Yoshioka T, Kawai T, Sakai H, TanizakiH, Heike T, Miyachi Y, Nakahata T. Role of the NOD2 genotype in the clinical phenotype of Blau syndrome and early-onsetsarcoidosis. Arthritis Rheum 2009; 60: 242-250 [PMID: 19116920DOI: 10.1002/art.24134].
  • 10Oliveira J, Hamdani N, Etain B, Bennabi M, Boukouaci W,Amokrane K, Fortier C, Marzais F, Bengoufa D, Bellivier F, HenryC, Kahn JP, Charron D, Krishnamoorthy R, Leboyer M, TamouzaR. Genetic association between a 'standing' variant of NOD2 andbipolar disorder. Immunobiology 2014; 219: 766-771 [PMID:25053139 DOI: 10.1016/j.imbio.2014.06.003].

同被引文献9

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部